Thursday, November 19, 2026 | 11am EST: Accelerating Early-Stage Oncology Global Drug Development

X

OXB and Aura Biosciences Partner on Phase III Eye Cancer Program

Aura Biosciences is studying bel-sar for early choroidal melanoma, with the aim of controlling tumor growth while preserving vision.

Aura Biosciences is studying bel-sar for early choroidal melanoma, with the aim of controlling tumor growth while preserving vision.

The partnership includes designated production capacity and preparations for commercial supply if bel-sar receives approval.

Drug manufacturer OXB has confirmed a partnership with Aura Biosciences to support belzupacap sarotalocan (bel-sar), an experimental eye cancer treatment in Phase III testing. The agreement also covers preparations for commercial supply if the treatment is approved.

OXB will support the program through its development facility in Bedford, Massachusetts, and its FDA-approved manufacturing facility in Durham, North Carolina. The Durham site can produce the drug substance and fill it into its final containers.

OXB has begun transferring the manufacturing process to its facilities ahead of process performance qualification. This checks whether the process can consistently produce medicine that meets required quality standards.

Xtalks Insights

Get industry leading pharma and biotech news, events and expert insights delivered to your inbox.

What topics would you like to hear more about?

Select all that apply.

Want to get even more specific?

Help us narrow down the sub-topics that you're most interested in.

Thank you!

For webinars, videos, podcasts and more from Xtalks, join our community today.

BECOME A FREE MEMBER

The companies are setting aside manufacturing capacity for bel-sar. Aura expects this arrangement to give it greater long-term control over production scheduling.

Bel-sar is a virus-like drug conjugate, which links a particle that attaches to cancer cells with a light-sensitive dye. An eye laser activates the dye, producing reactive oxygen molecules designed to destroy the cancer cells. This process may also prompt the immune system to attack the cancer.

Aura’s most advanced study is in early choroidal melanoma, a cancer in the blood vessel-rich layer beneath the retina. The company is developing bel-sar to control tumor growth while preserving vision.

Its Phase III CoMpass trial enrolled 108 participants, all of whom have completed treatment and entered a 24-month follow-up period. Results from the trial’s main assessment at 15 months are expected in the second half of 2027.

CoMpass compares bel-sar with a sham procedure that mimics treatment. Researchers are measuring how long it takes for tumors to grow. A key secondary measure tracks how long participants go without either tumor growth or vision loss.

Bel-sar is delivered by suprachoroidal injection, into the space between the eye’s outer wall and the choroid, before laser activation.

Aura is also studying bel-sar for cancers that have spread to the choroid and cancers on the eye’s surface. It plans to share study details and timelines for results in the first quarter of 2027.

In broader clinical research news, Faeth Therapeutics, a biotech company developing cancer treatments, has also partnered with Roche. Faeth will test PIKTOR, its oral combination of serabelisib and sapanisertib, alongside Roche’s giredestrant in hormone receptor-positive, HER2-negative advanced breast cancer.

PIKTOR blocks several points in a pathway involved in cancer growth, while giredestrant targets and breaks down the estrogen receptor. Faeth will sponsor and run the Phase Ib/II study and retain all rights to PIKTOR.

And Labcorp is working with Grupo Fleury to expand clinical trial services in Brazil. Local assembly of trial kits is expected to begin in early 2027, followed by laboratory operations by year-end. Labcorp expects local assembly to shorten kit delivery times and reduce reliance on international shipping.


If you want your company to be featured on Xtalks.com, please email [email protected].